Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Stanford University
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
Vanderbilt-Ingram Cancer Center
H. Lee Moffitt Cancer Center and Research Institute